The report, released July 30, analyzed pharmacy program participants’ purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient’s analysts predicted a 3.70% drug price inflation rate for cardiopulmonary medication in 2025, slightly less than the predicted 3.81% overall drug price inflation rate.
The cardiology medications that saw the biggest share of spending were:
- Trikafta (elexacaftor/tezacaftor/ivacaftor): 0.58%
- Xolair (omalizumab): 0.52%
- Vyndamax (tafamidis): 0.50%
- Nucala (mepolizumab): 0.31%
- Creon, Zenpep (lipase/protease/amylase): 0.28%
- Entresto (sacubitril/valsartan): 0.26%
- Adrenalin (epinephrine): 0.23%
- Repatha (evolocumab): 0.20%
- Fasenra (benralizumab): 0.20%
- Pulmozyme (dornase alfa): 0.18%
The top cardiopulmonary medications with the greatest change in spend were:
- Norepinephrine bitartrate in 0.9% sodium chloride: 348% increase
- Leqvio (inclisiran sodium): 216% increase
- Tezspire (tezepelumab-ekko): 188% increase
- Phenylephrine HCI in .09% sodium chloride: 143% increase
- Vyndamax (tafamidis): 57% increase
- Trikafta (elexacaftor/tezacaftor/ivacaftor): 42% increase
- Repatha (evolocumab): 35% increase
- Entresto (sacubitril/valsartan): 26% increase
- Xolair (omalizumab): 10% increase
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
